QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane, QLD, 4006, Australia.
Infection Analytics Program, Kirby Institute for Infection and Immunity, UNSW Sydney, Sydney, 2052, Australia.
Malar J. 2022 Feb 16;21(1):49. doi: 10.1186/s12936-022-04075-z.
Artemisinin-based combination therapy (ACT) has been a mainstay for malaria prevention and treatment. However, emergence of drug resistance has incentivised development of new drugs. Defining the kinetics with which circulating parasitized red blood cells (pRBC) are lost after drug treatment, referred to as the "parasite clearance curve", has been critical for assessing drug efficacy; yet underlying mechanisms remain partly unresolved. The clearance curve may be shaped both by the rate at which drugs kill parasites, and the rate at which drug-affected parasites are removed from circulation.
In this context, two anti-malarials, SJ733, and an ACT partner drug, pyronaridine were compared against sodium artesunate in mice infected with Plasmodium berghei (strain ANKA). To measure each compound's capacity for pRBC removal in vivo, flow cytometric monitoring of a single cohort of fluorescently-labelled pRBC was employed, and combined with ex vivo parasite culture to assess parasite maturation and replication.
These three compounds were found to be similarly efficacious in controlling established infection by reducing overall parasitaemia. While sodium artesunate acted relatively consistently across the life-stages, single-dose SJ733 elicited a biphasic effect, triggering rapid, partly phagocyte-dependent removal of trophozoites and schizonts, followed by arrest of residual ring-stages. In contrast, pyronaridine abrogated maturation of younger parasites, with less pronounced effects on mature parasites, while modestly increasing pRBC removal.
Anti-malarials SJ733 and pyronaridine, though similarly efficacious in reducing overall parasitaemia in mice, differed markedly in their capacity to arrest replication and remove pRBC from circulation. Thus, similar parasite clearance curves can result for anti-malarials with distinct capacities to inhibit, kill and clear parasites.
基于青蒿素的联合疗法(ACT)一直是疟疾预防和治疗的主要方法。然而,药物耐药性的出现促使新药物的开发。定义药物治疗后循环寄生红细胞(pRBC)丧失的动力学,称为“寄生虫清除曲线”,对于评估药物疗效至关重要;然而,潜在的机制仍未完全解决。清除曲线的形状可能既取决于药物杀死寄生虫的速度,也取决于受药物影响的寄生虫从循环中清除的速度。
在这种情况下,两种抗疟药 SJ733 和一种 ACT 联合用药吡喹酮与青蒿琥酯钠在感染伯氏疟原虫(ANKA 株)的小鼠中进行了比较。为了测量每种化合物在体内清除 pRBC 的能力,采用流式细胞术监测单一批次荧光标记的 pRBC,并结合体外寄生虫培养来评估寄生虫成熟和复制。
这三种化合物在控制已建立的感染方面同样有效,通过减少总体寄生虫血症来实现。虽然青蒿琥酯钠在整个生命周期中表现相对一致,但单剂量 SJ733 引发了双相作用,迅速触发,部分依赖吞噬细胞,清除滋养体和裂殖体,然后停止残留的环期。相比之下,吡喹酮阻断了较年轻寄生虫的成熟,对成熟寄生虫的影响较小,同时适度增加 pRBC 的清除。
尽管 SJ733 和 pyronaridine 这两种抗疟药在减少小鼠总体寄生虫血症方面同样有效,但它们在阻止寄生虫复制和清除循环中的 pRBC 方面的能力却有明显差异。因此,对于具有不同抑制、杀伤和清除寄生虫能力的抗疟药,可能会产生相似的寄生虫清除曲线。